SWHR Letter to ICER on Draft Evidence Report for Alzheimer’s Drug Aducanumab


Published 6/2/21

In a letter to the Institute for Clinical and Economic Review (ICER), SWHR expressed concern over the methodology and conclusions of ICER’s Effectiveness and Value Draft Evidence Report for aducanumab, a new potential treatment of Alzheimer’s disease (AD).

Last fall, SWHR provided input encouraging ICER to analyze data on sex and gender differences in AD and account for them in its model analysis plan. SWHR also suggested that ICER should consider for comparison all available evidence-based options, including behavioral therapies and lifestyle interventions. Finally, SWHR asked that ICER quantitatively account for the public health burden of AD in its cost-effectiveness methodologies and that ICER include factors that impact women disproportionately (like caregiver burden) in its model analysis plan.

SWHR’s latest letter states that the draft evidence report “fails to take into account the totality of scientific evidence and factors that an approved therapy might have on an individual with AD, as well as their caregivers.” For women in particular, it is important that ICER’s methodologies take into account the burden of AD on women as both patients and caregivers, and recognize the burden that could be assuaged by new therapies that have the potential to lengthen and improve quality of life.

Read The Letter